Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
PZ HTL SA
GLOBETECH PUBLISHING LLC

Imidazopyrazines Kill the Malaria Parasite at Every Stage of Its Life Cycle

By BiotechDaily International staff writers
Posted on 09 Dec 2013
Image: Malaria parasites (labeled with fluorescent protein) in the late stages of development, superimposed on a field of red blood cells. The many nuclei of the parasites\' daughter cells are labeled in blue, and the plasma membranes surrounding the daughter cells are labeled in green. Imidazopyrazine treatment disrupts formation of the membranes around the daughter cells (Photo courtesy of Dr. Marcus C.S. Lee, Columbia University Medical Center).
Image: Malaria parasites (labeled with fluorescent protein) in the late stages of development, superimposed on a field of red blood cells. The many nuclei of the parasites\' daughter cells are labeled in blue, and the plasma membranes surrounding the daughter cells are labeled in green. Imidazopyrazine treatment disrupts formation of the membranes around the daughter cells (Photo courtesy of Dr. Marcus C.S. Lee, Columbia University Medical Center).
An enzyme that is vital to all life stages of several species of malaria parasites has been cited as a tempting target for drug developers.

Achieving the goal of malaria elimination will depend on targeting pathways essential across all life stages of the parasite, Plasmodium. Towards this end, investigators at Columbia University Medical Center (New York, NY, USA) collaborated with an international team of researchers to screen more than a million drug compounds against the most lethal malaria parasite, Plasmodium falciparum, in order to identify compounds capable of killing the parasite at each stage of its life cycle.

They reported in the November 27, 2013, online edition of the journal Nature that the class of compounds called imidazopyrazines was capable of inhibiting the intracellular development of P. falciparum and several other species including P. vivax and P. cynomolgi at every stage of infection in the vertebrate host.

Imidazopyrazines demonstrated potent preventive, therapeutic, and transmission-blocking activity in rodent malaria models and were active against blood-stage field isolates of the major human pathogens P. falciparum and P. vivax. In addition, they inhibited liver-stage hypnozoites in the simian parasite P. cynomolgi.

The target of imidazopyrazine inhibition was found to be the enzyme phosphatidylinositol 4-kinase (PI(4)K). Imidazopyrazines altered the intracellular distribution of phosphatidylinositol-4-phosphate in the parasite's Golgi organelle by occupying PI(4)K's ATP-binding pocket.

“We think that disrupting the function of PI(4)K at the Golgi stops the parasite from making new membranes around its daughter cells, thereby preventing the organism from reproducing,” said senior author Dr. Marcus C. S. Lee, associate research scientist in microbiology and immunology at Columbia University Medical Center.

“Perhaps the most exciting aspect of our findings is that this enzyme is required at all stages of the parasites’ life cycle in humans,” said Dr. Lee. “This is important because most antimalarials are effective at killing the parasites only as they circulate in the bloodstream. However, the parasites can hide in the liver for years before reemerging and triggering a relapse of the disease. By identifying this enzyme, we may be able to develop a new way to kill the parasites in their dormant stage.”

Related Links:

Columbia University Medical Center



BIOSIGMA S.R.L.
SLAS - Society for Laboratory Automation and Screening
RANDOX LABORATORIES
comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: A 3-dimensional picture reveals how the antibodies in the experimental drug Zmapp bind to Ebola virus (Photo courtesy of the Scripps Research Institute).

Electron Microscope Imaging Shows How Experimental Anti-Ebola Drug Works

Electron microscope imaging has revealed how the experimental drug ZMapp binds to the Ebolavirus and provides insights into how the drug prevents growth of the pathogen. ZMapp, which was developed by... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Lab Technologies

view channel

e-Incubator Technology Provides Real-Time Imaging of Bioengineered Tissues in a Controlled Unit

A new e-incubator, an innovative miniature incubator that is compatible with magnetic resonance imaging (MRI), enables scientists to grow tissue-engineered constructs under a controlled setting and to study their growth and development in real time without risk of contamination or damage. Offering the potential to test... Read more

Business

view channel

Two Industry Partnerships Initiated to Fuel Neuroscience Research

Faster, more complex neural research is now attainable by combining technology from two research companies. Blackrock Microsystems, LLC (Salt Lake City, UT, USA), a developer of neuroscience research equipment, announced partnerships with two neuroscience research firms—PhenoSys, GmbH (Berlin, Germany) and NAN Instruments, Ltd.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.